# Effects of Insulin Glargine and Lixisenatide on the Brain

> **NCT03881995** · PHASE4 · TERMINATED · sponsor: **University Hospital Tuebingen** · enrollment: 1 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** IGlarLixi
- **DRUG:** Insulin Glargine 100 UNT/ML

## Key facts

- **NCT ID:** NCT03881995
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-18
- **Primary completion:** 2020-06-29
- **Final completion:** 2020-06-29
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** insufficient recruitment
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881995, "Effects of Insulin Glargine and Lixisenatide on the Brain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03881995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*